Organogenesis Inc. Announces Acquisition of Dermagraft® from Shire

      Organogenesis Inc. Announces Acquisition of Dermagraft® from Shire

Product Acquisition Solidifies Organogenesis Position as Industry Leader

PR Newswire

CANTON, Mass., Jan. 17, 2014

CANTON, Mass., Jan. 17, 2014 /PRNewswire/ -- Organogenesis Inc., a commercial
leader in the field of regenerative medicine, announced today that it has
purchased the Dermagraft® assets (human fibroblast-derived dermal substitute)
from Shire plc (LSE: SHP, NASDAQ: SHPG).

"Organogenesis is a pioneering company in the regenerative medicine and wound
healing fields, and we are now the proud owners of two products containing
living cells that are FDA-approved for wound healing. In the midst of a CMS
coverage decision which limits access to FDA-proven technology, this deal was
necessary to keep both assets on the market and available for patient
treatment," said Geoff MacKay, president and Chief Executive Officer of
Organogenesis Inc. "We look forward to providing patients and clinicians with
Apligraf® and Dermagraft: two evidence-based, well-proven products designed to
heal chronic wounds."

Dermagraft is approved for the treatment of nonhealing diabetic foot ulcers in
the U.S. and Canada. Headquartered in Canton, Mass., Organogenesis will
continue to manufacture and distribute Dermagraft from its existing facilities
in La Jolla, Calif.

"In the U.S. alone, more than three million people are suffering from chronic
leg and foot wounds. As a physician dedicated to healing these wounds, this
is very exciting news," said Robert S. Kirsner, M.D., PhD, Professor, Vice
Chairman & Endowed Stiefel Laboratories Chair, Department of Dermatology &
Cutaneous Surgery, at the University of Miami Miller School of Medicine and
Chief of Dermatology for the University of Miami Hospital. "For many years,
Organogenesis has worked with clinicians and scientists to advance scientific
discussion and understanding of the field. It's terrific to see that, despite
recent changes in Medicare reimbursement that have threatened patient access
to wound healing products containing living cells, Organogenesis remains
committed to ensuring clinicians and their patients have evidence-based tools
and information to help heal these debilitating wounds."

About Organogenesis Inc.
Having pioneered the field, Massachusetts-based Organogenesis Inc. is a world
leading regenerative medicine company focused in the areas of bio-active wound
healing and oral regeneration. The company's mission is to bring the medical
marvel of regenerative medicine products to patients and to standardize their
use in everyday medical care. For more information, visit
www.organogenesis.com.

CONTACT:
Angelyn Lowe
(781) 830-2353
alowe@organo.com

SOURCE Organogenesis Inc.

Website: http://www.organogenesis.com
 
Press spacebar to pause and continue. Press esc to stop.